Physician profile
Michael Luna
NPI 1831308048
$3,623.54
in general payments reported to CMS, 2019-2025
8 companies · $2,272 in 2025
The $2,272 reported for 2025 was more than what 87% of Adult Congenital Heart Disease providers received nationally (typical 2025 total: $272).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $21.87 · 2021: $181 · 2022: $131 · 2023: $42.72 · 2024: $729 · 2025: $2,272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,679 · Travel and Lodging: $1,365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,678.67 |
| Travel and Lodging | $1,364.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,871.82 | 2024-2025 | Evoque, Edwards Sapien 3 Ultra Transcatheter Heart Valve, Pascal |
| Abbott Laboratories | $803.90 | 2019-2025 | Mitraclip, Navitor, Amplatzer Amulet |
| Medtronic, INC. | $377.82 | 2021-2025 | Corevalve Evolut R, Dxterity, Telescope |
| Shockwave Medical, INC | $225.09 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave M5+ |
| Abiomed | $149.74 | 2023-2025 | Impella |
| Boston Scientific Corporation | $100.83 | 2019-2024 | |
| Angiodynamics, INC. | $76.20 | 2022-2025 | Alphavac, Angiovac |
| Cardiva Medical, INC. | $18.14 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Luna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.